AAAAAA

   
Results: 1-7 |
Results: 7
Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: A multicenter randomized trial
Authors: Garcia-Carbonero, R Mayordomo, JI Tornamira, MV Lopez-Brea, M Rueda, A Guillem, V Arcediano, A Yubero, A Ribera, F Gomez, C Tres, A Perez-Gracia, JL Lumbreras, C Hornedo, J Cortes-Funes, H Paz-Ares, L
Citation: R. Garcia-carbonero et al., Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: A multicenter randomized trial, J NAT CANC, 93(1), 2001, pp. 31-38
Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer
Authors: Bellmunt, J Guillem, V Paz-Ares, L Gonzalez-Larriba, JL Carles, J Albanell, J Tabernero, JM Cortes-Funes, H Baselga, J
Citation: J. Bellmunt et al., Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer, EUR J CANC, 36, 2000, pp. S17-S25
Skin lesions in malignancy case 2. Skin metastases from prostate adenocarcinoma
Authors: Paz-Ares, L Olivia, E Carey, RW Smith, MR
Citation: L. Paz-ares et al., Skin lesions in malignancy case 2. Skin metastases from prostate adenocarcinoma, J CL ONCOL, 19(7), 2000, pp. 2099-2100
Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium
Authors: Bellmunt, J Guillem, V Paz-Ares, L Gonzalez-Larriba, JL Carles, J Batiste-Alentorn, E Saenz, A Lopez-Brea, M Font, A Nogue, M Bastus, R Climent, MA de la Cruz, JJ Albanell, J Banus, JM Gallardo, E Diaz-Rubio, E Cortes-Funes, H Baselga, J
Citation: J. Bellmunt et al., Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium, J CL ONCOL, 18(18), 2000, pp. 3247-3255
Tumor markers at the time of recurrence in patients with germ cell tumors
Authors: Trigo, JM Tabernero, JM Paz-Ares, L Garcia-Llano, JL Mora, J Lianes, P Esteban, E Salazar, R Lopez-Lopez, JJ Cortes-Funes, H
Citation: Jm. Trigo et al., Tumor markers at the time of recurrence in patients with germ cell tumors, CANCER, 88(1), 2000, pp. 162-168
Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion
Authors: Stevenson, JP DeMaria, D Sludden, J Kaye, SB Paz-Ares, L Grochow, LB McDonald, A Selinger, K Wissel, P O'Dwyer, PJ Twelves, C
Citation: Jp. Stevenson et al., Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion, ANN ONCOL, 10(3), 1999, pp. 339-344
Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer
Authors: Hidalgo, M Castellano, D Paz-Ares, L Gravalos, C Diaz-Puente, M Hitt, R Alonso, S Cortes-Funes, H
Citation: M. Hidalgo et al., Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer, J CL ONCOL, 17(2), 1999, pp. 585-592
Risultati: 1-7 |